Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …

In this first-in-human, investigator-initiated, open-label study, three participants with recurrent
glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor …

Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …

Human cancers are complex ecosystems composed of cells with distinct phenotypes,
genotypes, and epigenetic states, but current models do not adequately reflect tumor …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …

Recombinant antibodies are highly specific detection probes in research, diagnostics, and
have emerged over the last two decades as the fastest growing class of therapeutic proteins …

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …

Despite all of the progress in understanding its molecular biology and pathogenesis,
glioblastoma (GBM) is one of the most aggressive types of cancers, and without an efficient …